Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-535-8 | CAS number: 2457-01-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- June - July 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- issued 2012-07-18
- Test type:
- acute toxic class method
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 2.018g/10mL (high dose), 0.3005 and 0.3004g/10mL (low dose)
- MAXIMUM DOSE VOLUME APPLIED: 10mL/kg bw - Doses:
- 300, 2000 mg/kg bw
- No. of animals per sex per dose:
- Dose group 2000mg/kg bw: 3 animals
Dose group 300mg/kg bw: 6 animals - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: daily
- Necropsy of survivors performed: yes
- Other examinations performed: behavioural or toxic effects on the major physiological functions - Statistics:
- not performed
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - <= 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 3/3 in 2000mg/kg bw dose group, 1h post dose
1/6 in 300mg/kg bw dose group, 23h 15min post dose - Clinical signs:
- other: 2000mg/kg bw dose group: absence of spontaneous activity (3/3), Preyer's reflex (3/3), righting reflex (3/3), muscle tone (3/3), bradypnoea (3/3), salvation (1/3) 300mg/kg bw dose group: decrease of spontaneous activity (2/5), salvation (2/5), piloerectio
- Gross pathology:
- 2000mg/kg bw dose group: white colouration of the forestomach (3/3), red spots on the corpus (3/3)
300mg/kg bw dose group: rigor mortis before necropsy, marked lysis prevented macroscopic examination, surviving animals did not reveal treatment related changes - Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The LD50 of the test item barium bis(2-ethylhexanoate) is higher than 300mg/kg bw and lower than 2000mg/kg bw by oral route in the rat.
In accordance with directive 67/548/EEC, the test item barium bis(2-ethylhexanoate) has to be classified with Xn, R22 (Harmful if swallowed).
In accordance with regulation (EC) 1272/2008 the test item barium bis(2-ethylhexanoate) has to be classified in category 4, H302 (Harmful if swallowed) and the signal word "Warning" be assigned.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Quality of whole database:
- One key study available (according to OECD 423, under GLP) which is reliable without restrictions (RL=1). The overall quality of the database is therefore high.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
- all available proprietary studies from the Metal carboxylates REACH Consortium (MCRC)
- detailed literature searches in online databases
- screening of human health review articles
- rigorous quality and reliability screening according to Klimisch criteria, where those criteria apply
Introduction
A comprehensive data gap analysis was conducted for the entire substance portfolio of the Metal carboxylates REACH Consortium (MCRC), covering 10 metal carboxylates in total. This literature screening effort included:
During the literature search and data gap analysis it became obvious that the overall database on substance-specific human health hazard data for the metal carboxylates is too scant to cover all REACH endpoints. Therefore, the remaining data gaps had to be covered by either experimental testing or read-across from similar substances.
Selected endpoints for the human health hazard assessment are addressed by read-across, using a combination of data on the organic acid counterion and the metal (or one of its readily soluble salts). This way forward is acceptable, since metal carboxylates dissociate to the organic anion and the metal cation upon dissolution in aqueous media. No indications of complexation or masking of the metal ion through the organic acid were apparent during the water solubility tests (please refer to the water solubility data in section of the IUCLID and chapter of the CSR). Once the individual constituents of the metal carboxylate become bioavailable (i.e. in the acidic environment in the gastric passage or after phagocytosis by pulmonary macrophages), the “overall” toxicity of the dissociated metal carboxylate can be described by the toxicity of the “individual” constituents. Since synergistic effects are not expected for this group of metal carboxylates, the human health hazard assessment consists of an individual assessment of the metal cation and the organic anion.
The hazard information of the individual constituents was obtained from existing REACH registration dossiers via a license-to-use obtained by the lead registrant. These registration dossiers were submitted to ECHA in 2010 as full registration dossiers, and are thus considered to contain relevant and reliable information for all human health endpoints. All lead-registrant dossiers were checked for completeness and accepted by ECHA, i.e. a registration number was assigned.
Barium bis(2-ethylhexanoate) is the barium metal salt of 2-ethylhexanoic acid, which readily dissociates to the corresponding metal barium cation and 2-ethylhexanoic anions. The barium cation and the 2-ethylhexanoic acid anion are considered to represent the overall toxicity of barium bis (2-ethylhexanoate) in a manner proportionate to the free acid and the metal (represented by one of its readily soluble salts). Based on the above information, unrestricted read-across is considered feasible and justified.
Although the term „constituent“ within the REACH context is defined as substance (also being part of a mixture), the term constituent within this hazard assessment is meant to describe either part of the metal carboxylate salt, i.e. anion or cation.
Acute toxicity
No acute toxicity studies via inhalation and dermal route with barium bis(2-ethylhexanoate) are available. Acute inhalative and dermal acute toxicity will be addressed with existing data on the dissociation products as detailed in the table below. Further details on the acute toxicity of the individual constituents within the framework of regulation (EC) 1907/2006 are given below.
Table: Summary of acute toxicity data of barium bis(2-ethylhexanoate) and the individual constituents.
|
BaCl2 (CAS# 10361-37-2) |
2-ethylhexanoic acid (CAS# 149-57-5) |
Barium bis(2-ethylhexanoate) |
Acute inhalation toxicity |
LC50>1mg/L Acute Tox 4 (H332) |
LD0= 0.11 mg/L air (nominal) |
waived, since the substance is used and placed on the market in a non-inhalable form |
Acute dermal toxicity |
LD50(rat)>2,000 mg/kg bw |
LD50> 2,000 mg/kg bw |
LD50>2,000 mg/kg bw (calculated) |
The acute dermal toxicity for barium bis(2-ethylhexanoate) is > 2000mg/kg bw, since both constituents have shown no sign of acute dermal toxicity. Hence the substance is not to be classified according to regulation (EC) 1272/2008 for acute dermal toxicity.
In a study according to OECD 423 and under GLP, the LD50 of the test item barium bis(2-ethylhexanoate) was determined to be higher than 300mg/kg bw and lower than 2000mg/kg bw by oral route in the rat.
Further testing is not required. For further information on the toxicity of the individual constituents, please refer to the relevant sections in the IUCLID and CSR.
Justification for selection of acute toxicity – oral endpoint
Key study
Justification for selection of acute toxicity – inhalation endpoint
Endpoint waived, since the substance is used and placed on the market in a non-inhalable form.
Justification for selection of acute toxicity – dermal endpoint
Read-across information.
Justification for classification or non-classification
Furthermore, no classification for specific target organ toxicity, single exposure (STOT SE) is required based on the acute dermal toxicity data.
In a study according to OECD 423 and under GLP, the LD50 of the test item barium bis(2-ethylhexanoate) was determined to be higher than 300mg/kg bw and lower than 2000mg/kg bw by oral route in the rat.
In accordance with directive 67/548/EEC, the test item barium bis(2-ethylhexanoate) has to be classified with Xn, R22 (Harmful if swallowed).
In accordance with regulation (EC) 1272/2008 the test item barium bis(2-ethylhexanoate) has to be classified in category 4, H302 (Harmful if swallowed) and the signal word "Warning" be assigned.
This classification is in accordance with tables 3.1 and 3.2 REGULATION (EC) No 1272/2008, Index No: 056-002-7 (barium salts in general) for acute oral and inhalative toxicity (Cat 4/H302, H332; Xn R20/22).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.